GlassScriptPhysician profile
Ruksana Papa
NPI 1235196635
$1,395.04
in general payments reported to CMS, 2019-2025
13 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.28 · 2020: $16.01 · 2021: $48.53 · 2022: $453 · 2023: $469 · 2024: $133 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.67 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.87 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $295.14 | 2021-2025 | |
| Lilly USA, LLC | $148.41 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Idorsia Pharmaceuticals US INC | $136.18 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $114.70 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $73.13 | 2023 | Gemtesa |
| Corium, LLC | $68.98 | 2022-2023 | Adlarity |
| Amgen INC. | $41.19 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $37.91 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $29.61 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $22.66 | 2023 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.90 | 2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruksana Papa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.